The health care needs of children with spina bifida are complex. They need specialists, generalists, and an integrated system to deliver this complex care and to align and inform all the providers. Most research in spina bifida has been focused on narrow medical outcomes; it has been noncollaborative, based on small samples of convenience, with no comparison groups, and without consistent standards of measurement. Models of health, like the World Health Organization International Classification of Functioning, Disability, and Health Model can help to broaden the scope of future research. Using methods from other pediatric conditions like the patient registry (cystic fibrosis), gene bank (autism), and collaborative research (leukemia), researchers can improve the quality of future studies. Research questions related to the process of care and to specific nonsurgical conditions associated with spina bifida are reviewed in this article.

With modern risk-adapted therapy, over 80% of children with acute lymphoblastic leukemia (ALL) in highincome countries (HICs) are cured. In countries with limited resources, however, therapy results for pediatric ALL are still not encouraging. We describe our experience in treating children with ALL using a risk-adapted protocol at a tertiary referral center in Lebanon. From May 2002 to August 2009, 111 consecutive patients 1-21 years of age with newly diagnosed ALL received the CCCL ALL protocol which was based on the St. Jude Children's Research Hospital Total XV Study. The median age at diagnosis was 5 years 5 months. The male to female ratio was 1.5. Forty-six patients received the intermediate-/high-risk arm and 65 received the low-risk arm. Only one patient (0.9%) died during induction therapy. Relapse occurred in 8 (7.2%) patients. Eight (7.2%) patients died, 4 of whom were in remission. The median follow-up of the patients was 38 months. The 5-year overall survival and event-free survival were and 88.5% (95% CI: 77.1-94.4) and 78.7% (95% CI: 69.8-88.4), respectively. Our results are comparable to those in HICs in spite of the limited resources and the relatively low socioeconomic status of the Lebanese population. Children treated on this protocol experienced significant toxicity necessitating expert supportive care, but benefited from improved cure rates and prolonged survival. Am. J. Hematol. 87:678-683, 2012. V

Malignant peripheral nerve sheath tumors (MPNST) are uncommon in children and almost half of the cases occur in patients with neurofibromatosis 1 (NF1). We report a child with a primary MPNST of the lung without NF1. MPNST of the lung has similar clinical and radiologic characteristics as pleuropulmonary blastoma. We suggest to include MPNST of the lung in the differential diagnosis of intrapulmonary masses in children.

Neonatal AKI is underappreciated, particularly among neonatologists. A lack of evidence on neonatal AKI contributes to this variation in response. Therefore, dissemination of current knowledge and areas for research should be the priority.

876 Background: Acute lymphoblastic leukemia (ALL) represents about 25% of all pediatric cancers. With modern risk adapted therapy over 80% of children with ALL are cured in developed countries. In countries with limited resources, however, therapy results for pediatric ALL are still not encouraging. We herein describe our experience in adopting an aggressive ALL protocol and the results and complications of using this risk-adapted protocol for treating children with ALL at a tertiary referral center in Lebanon. Patients: From May 2002 to August 2009, 110 consecutive patients 1–21 years of age with newly diagnosed ALL received the CCCL ALL protocol which was based on the St. Jude Children's Research Hospital Total XV Study. Patients were classified into one of three categories: low, standard, or high risk. Results: The clinical and laboratory characteristics of patients are presented in Table 1. The median age at diagnosis was 5 years 5 months. The male to female ratio was 1.5. Forty-six patients received the standard/high risk arm and 64 received the low risk arm. One patient (0.91%) died during induction therapy. Relapse occurred in 7 (6.4%) patients; 2 patients with T-cell ALL and WBC count >100 × 109/L developed CNS relapse during maintenance therapy, and 5 patients developed bone marrow relapse. During induction chemotherapy, patients had the following complications: 17 (15.4%) patients developed febrile neutropenia, 12 diarrhea, 6 tumor lysis syndrome, 1 typhlitis, 2 SIADH, and 2 hypertension. In addition, one patient had nasal septal aspergillosis, 1 influenza A infection, 2 sinusitis, 4 extremity cellulitis, 1 orbital cellulitis, 3 thrombosis (1 femoral line and 2 extremity). Complications during consolidation and maintenance included fever and neutropenia, pneumonia, recurrent otitis media, sinusitis, cellulitis of the face, herpes zoster, diarrhea, as well as gram positive and gram negative septicemia. Two patients died of Escherichia coli (ESBL) septic shock. Cytomegalovirus (CMV) retinitis was diagnosed in 4 patients; all were treated with gancyclovir. One patient developed PML (progressive multi-focal leukoencephalopathy). Three patients developed PRES (posterior reversible encephalopathy syndrome). Five patients developed sagittal sinus thrombosis and 5 developed pancreatitis secondary to L-asparaginase. Eight (7.3%) patients died, 4 (3.6%) of whom were in remission. None of the patients developed a secondary malignancy. The median follow up of the patients was 37.7 months (range 1.7–89.3) and the estimated mean survival time was 82.4 months (95% CI: 77.8–87.0). The 5-year overall survival and event-free survival were and 88.4% and 79.5%, respectively (Figure 1 & 2). Conclusions: Our results are comparable to those in developed countries in spite of the limited resources and the relatively low socioeconomic status of the Lebanese population. This treatment protocol was effective in improving the survival rates of children with ALL at our institution. Despite the fact that we had significant toxicity, there was a great advance in outcome reflected in the prolonged survival and improved cure rates. An aggressive risk stratified ALL protocol may be implemented successfully in a developing country but the toxicity profile may be completely different and more severe compared to that of developed countries. Disclosures: Muwakkit: Children's Cancer Center of Lebanon: Research Funding.